Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dual Phase I Studies to Determine the Dose of Cediranib (AZD2171) or AZD6244 to Use With Conventional Rectal Chemoradiotherapy

NCT01160926 is registered in ClinicalTrials.gov with The Christie NHS Foundation Trust as lead sponsor.

NCT NCT01160926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01160926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dual Phase I Studies to Determine the Dose of Cediranib (AZD2171) or AZD6244 to Use With Conventional Rectal Chemoradiotherapy
Lead sponsor
The Christie NHS Foundation Trust
Phase
Phase 1
Overall status
Terminated
Start date
July 31, 2010
Completion date
November 4, 2016
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer